News and Announcements
Dr Antony Rapisarda of OrthoDx™
- Published December 06, 2022 6:56AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
OrthoDx™ is a privately held company based out of Sydney, Australia, focused on the development and commercialization of novel genomic biomarkers for use in the diagnosis of joint pain. The primary function of the first genomic signature for clinical use is to aid surgeons and physicians to differentiate between infection-negative and infection-positive synovial joint inflammation in adults.
Watch this interview with CEO Dr. Antony Rapisarda as he discusses SynvIchor™, their biomarker technology and the company’s current and future milestones.
Executive Interviews
Beyond Strategy: Why Your Network Will Define Your Business Exit
Beyond operational readiness, a strong, purpose-built network is crucial for a successful business exit. Learn how an “exit ecosystem” of advisors, capital partners, and fellow founders can define the outcome of your most significant transaction.
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders
The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]
IPO Bound: The Strategic Edge Guiding Australian Investors to India’s Next Unicorns
Uncover Creek Partners’ strategic vision for Australian investors in India’s booming economy. From IPO-bound deals to pioneering tech exchange, this playbook reveals how to navigate and profit from a market set to hit $7 trillion.
Backed By Leading Investment Groups and Family Offices
